Skip to main content
. 2019 May 17;13(6):6477–6490. doi: 10.1021/acsnano.8b09613

Figure 1.

Figure 1

Tumor-membrane coated TOPSi@AcDEX nanovaccines are cytocompatible and induce the maturation of murine APCs in vitro. (A) Cell viability (%) of JAWS II cells incubated with the tumor-membrane-coated TOPSi@AcDEX nanovaccine (NanoCCM) for 24 h (left) and 48 h (right), as such or in the presence of two different concentrations of a murine anti-CTLA4 antibody. Cells incubated in 10% medium and in Triton X-100 1% represent the negative and positive controls. (B) Percentage of CD80, CD86, and double positive JAWS II cells after 48 h (top) and 72 h (bottom). JAWS II cells were incubated with APC antimouse CD80+ antibody or PerCP-Cy 5.5 antimouse CD86+ antibodies, and the expression of the receptors was evaluated by flow cytometry. The cells were incubated with NanoCCM at the concentration of 100 μg/mL for 48 and 72 h. Cells incubated with medium and cells incubated with LPS represent the negative and positive controls, respectively. The results are expressed as mean ± SD (n > 3) and were analyzed with two-way ANOVA followed by Bonferroni post-test. *p < 0.05, **p < 0.01, and ***p < 0.001.